Dr Babafemi Taiwo is a Nigerian leading part of the study of a drug called Remdesivir that has proved effective for the treatment of COVID19.
He is Chief of infectious diseases at Northwestern University Feinberg School of Medicine in Chicago.
Dr Babafemi Taiwo has been in practice for more than 20 years.
He is also Director, Clinical Core of the Third Coast Center for AIDS Research, and Leader of the Northwestern University Site of the NIAID-funded AIDS Clinical Trials Group (ACTG).
At Northwestern University, he leads clinical and translational HIV researchers from infectious diseases, hepatology, neurology, radiology, cardiology and nursing, and directs the development and implementation of NIH-sponsored interventional and observational HIV studies.
He has received research grants (to Northwestern) from industry sponsors for investigator-initiated studies.
Dr. Taiwo is the Director, Research in Africa, NU Center for Global Health. He has been involved in HIV treatment, research, and training in Nigeria for two decades.
His undergraduate education and initial medical training took place at the College of Medicine, University of Ibadan 1991.
He is Principal Investigator of the NIH D43 Multidisciplinary NeuroAIDS Training and Research Program in Nigeria
During an interview with CNN, the doctor said there is a promising result from the study Of Remdesivir.
“For the first time we have a large, well-conducted trial” showing a treatment helps, he said. “This is not a miracle drug … but it’s definitely better than anything we have.” .
“The Data that we have now shows good result”
The study, run by the National Institutes of Health, tested remdesivir versus usual care in 1,063 hospitalized coronavirus patients around the world. At the White House, NIH’s Dr. Anthony Fauci said the drug reduced the time it takes patients to recover by 31% — 11 days on average versus 15 days for those just given usual care.